A preclinical assay for chemosensitivity in multiple myeloma

Cancer Research

Volumn 74, Issue 1, 2014, Pages 56-67

  Khin, Zayar P ^a   Ribeiro, Maria L C ^a   Jacobson, Timothy ^a   Hazlehurst, Lori ^a   Perez, Lia ^a   Baz, Rachid ^a   Shain, Kenneth ^a   Silva, Ariosto S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MELPHALAN;

ARTICLE; BONE MARROW CANCER; BONE MARROW CULTURE; CELL POPULATION; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MEGADOSE; DRUG RESPONSE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MESENCHYME CELL; MICROFLUIDIC ANALYSIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPUTER SIMULATION; HUMANS; MICROFLUIDIC ANALYTICAL TECHNIQUES; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84892685866     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2397     Document Type: Article

References (36)

1. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995;13:1786-99.
2. Gardner SN. Amechanistic, predictive model of dose-response curves for cell cycle phase-specific and-nonspecific drugs. Cancer Res 2000;60:1417-25.
3. Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci 2008;99:140-4.
4. Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 2011;67:57-67.
5. Ishii T, Seike T, Nakashima T, Juliger S, Maharaj L, Soga S, et al. Antitumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J 2012;2:e68.
6. Suggitt M, BibbyMC. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clinical Cancer Research 2005;11:971-81.
7. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, et al. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983;43:1926-31.
8. Pellat-Deceunynk C, Amiot M, Bataille R, Van Riet I, Van Camp B, Omede P, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 1995;86:4001-2.
9. Hokanson JA, Brown BW, Thompson JR, Drewinko B, Alexanian R. Tumor growth patterns in multiple myeloma. Cancer 1977;39:1077-84.
10. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3: 90ra59.
11. Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood 2011;118:1622-31.
12. Gardner SN, Fernandes M. New tools for cancer chemotherapy: computational assistance for tailoring treatments. Mol Cancer Ther 2003;2:1079-84.
13. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978;298:1321-7.
14. Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: empirical totarget-drivenapproaches. ClinCancerRes2005;11:971-81.
15. Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, Belch AR, et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 2008;112:2935-45.
16. Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 2004;22:1857-63.
17. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139-46.
18. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009;9:665-74.
19. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-26.
20. Thevenaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process 1998;7: 27-41.
21. Sternberg SR. Biomedical image processing. Computer 1983;16: 22-34.
22. Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res 2012;72:6362-70.
23. Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, et al. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Mol Cancer Ther 2009;8:2441-51.
24. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 1991;51:995-1002.
25. Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006;12:591-9.
26. Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res 2010;16:2792-802.
27. Ishii T, Seike T, Nakashima T, Juliger S, Maharaj L, Soga S, et al. Antitumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J 2012;2:e68.
28. Williamson MJ, Silva MD, Terkelsen J, Robertson R, Yu L, Xia C, et al. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol Cancer Ther 2009;8:3234-43.
29. Misund K, Baranowska KA, Holien T, Rampa C, Klein DC, Borset M, et al. A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells. J Biomol Screen 2013;18:637-46.
30. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
31. Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 2009;69: 6899-905.
32. Wells A, Griffith L, Wells JZ, Taylor DP. The dormancy dilemma: quiescence versus balanced proliferation. Cancer Res 2013;73:3811-6.
33. San-Miguel JF, Mateos MV. Can multiple myeloma become a curable disease? Haematol-Hematol J 2011;96:1246-8.
34. Silva AS, Gatenby RA. A theoretical quantitative model for evolution of cancer chemotherapy resistance. Biol Direct 2010;5:25.
35. Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res 2012;72:6362-70.
36. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152:714-26.